Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

1-25 of 38 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2

Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long-term extension results.
Turner D, Rosh JR, Cohen SA, Griffiths AM, Hyams JS, Kierkuś J, Adedokun OJ, Strauss R, Kim L, Volger S, UniStar Study Group
J Pediatr Gastroenterol Nutr, 79(2):315-324, 27 May 2024
Cited by: 0 articles | PMID: 38801079
Add to export list
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease.
Colombel JF, Sands BE, Gasink C, Yeager B, Adedokun OJ, Izanec J, Ma T, Gao LL, Lee SD, Targan SR, Ghosh S, Hanauer SB, Sandborn WJ
Clin Gastroenterol Hepatol, 22(1):144-153.e2, 28 Jun 2023
Cited by: 2 articles | PMID: 37391056
Add to export list
Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease.
Adedokun OJ, Xu Z, Gasink C, Kowalski K, Sandborn WJ, Feagan B
Clin Ther, 44(10):1336-1355, 21 Sep 2022
Cited by: 6 articles | PMID: 36150926
Add to export list
Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis.
Lee JB, Broadwell A, Fan Y, Hu C, Adedokun OJ, Chakravarty SD, Zhou H, Xu Z, Leu JH
Clin Ther, 44(3):457-464.e2, 17 Feb 2022
Cited by: 1 article | PMID: 35183373
Add to export list
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, [...] GALAXI-1 Investigators
Gastroenterology, 162(6):1650-1664.e8, 05 Feb 2022
Cited by: 54 articles | PMID: 35134323
Add to export list
Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.
Rosh JR, Turner D, Griffiths A, Cohen SA, Jacobstein D, Adedokun OJ, Padgett L, Terry NA, O'Brien C, Hyams JS
J Crohns Colitis, 15(11):1931-1942, 01 Nov 2021
Cited by: 20 articles | PMID: 34037715 | PMCID: PMC8575045
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG, Lynch JP
Clin Gastroenterol Hepatol, 20(3):578-590.e4, 19 Feb 2021
Cited by: 72 articles | PMID: 33618023 | PMCID: PMC8374005
Add to export list Free full text in Europe PMC
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Arasaradnam RP, Sands BE, Marano C
Aliment Pharmacol Ther, 52(11-12):1658-1675, 21 Oct 2020
Cited by: 27 articles | PMID: 33086438 | PMCID: PMC8776399
Add to export list Free full text in Europe PMC
Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results.
Hyams JS, O'Brien CD, Padgett L, Rosh JR, Turner D, Veereman G, Griffiths AM, Heyman MB, Wahbeh G, Adedokun OJ, Strauss RS, Lynch JP, Chan D
Crohns Colitis 360, 2(4):otaa063, 04 Aug 2020
Cited by: 3 articles | PMID: 36777743 | PMCID: PMC9802358
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis.
Xu Y, Hu C, Chen Y, Miao X, Adedokun OJ, Xu Z, Sharma A, Zhou H
J Clin Pharmacol, 60(7):889-902, 05 Feb 2020
Cited by: 11 articles | PMID: 32026499
Add to export list
Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
Adedokun OJ, Xu Z, Liao S, Strauss R, Reinisch W, Feagan BG, Sandborn WJ
Clin Ther, 42(1):157-174.e4, 22 Jan 2020
Cited by: 6 articles | PMID: 31982148
Add to export list
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, Van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ
Clin Gastroenterol Hepatol, 18(10):2244-2255.e9, 07 Dec 2019
Cited by: 37 articles | PMID: 31816446
Add to export list
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S
J Crohns Colitis, 14(1):23-32, 01 Jan 2020
Cited by: 90 articles | PMID: 31158271
Add to export list
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C, UNIFI Study Group
N Engl J Med, 381(13):1201-1214, 01 Sep 2019
Cited by: 430 articles | PMID: 31553833
Add to export list
Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis.
Adedokun OJ, Gunn GR, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P, Shankar G
Inflamm Bowel Dis, 25(9):1532-1540, 01 Aug 2019
Cited by: 9 articles | PMID: 30753466
Add to export list
Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Leu JH, Adedokun OJ, Gargano C, Hsia EC, Xu Z, Shankar G
Rheumatology (Oxford), 58(3):441-446, 01 Mar 2019
Cited by: 13 articles | PMID: 30412238
Add to export list
Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis.
Xu Y, Adedokun OJ, Chan D, Hu C, Xu Z, Strauss RS, Hyams JS, Turner D, Zhou H
J Clin Pharmacol, 59(4):590-604, 11 Dec 2018
Cited by: 10 articles | PMID: 30536638
Add to export list
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB
Clin Gastroenterol Hepatol, 17(8):1525-1532.e1, 26 Sep 2018
Cited by: 71 articles | PMID: 30267864
Add to export list
Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.
Hu C, Adedokun OJ, Zhang L, Sharma A, Zhou H
J Pharmacokinet Pharmacodyn, 45(6):803-816, 30 Oct 2018
Cited by: 7 articles | PMID: 30377888
Add to export list
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ
Gastroenterology, 155(4):1045-1058, 29 Aug 2018
Cited by: 66 articles | PMID: 29909019
Add to export list
Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension.
Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C
J Crohns Colitis, 12(9):1053-1066, 01 Aug 2018
Cited by: 10 articles | PMID: 29917070
Add to export list
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ
Gastroenterology, 154(6):1660-1671, 01 Feb 2018
Cited by: 104 articles | PMID: 29409871
Add to export list
Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit.
Hyams JS, Chan D, Adedokun OJ, Padgett L, Turner D, Griffiths A, Veereman G, Heyman MB, Rosh JR, Wahbeh G, Strauss R
Inflamm Bowel Dis, 23(12):2227-2237, 01 Dec 2017
Cited by: 18 articles | PMID: 29140944
Add to export list
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.
Hu C, Adedokun OJ, Chen Y, Szapary PO, Gasink C, Sharma A, Zhou H
J Pharmacokinet Pharmacodyn, 44(5):425-436, 16 Jun 2017
Cited by: 4 articles | PMID: 28623612
Add to export list
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, [...] UNITI–IM-UNITI Study Group
N Engl J Med, 375(20):1946-1960, 01 Nov 2016
Cited by: 772 articles | PMID: 27959607
Add to export list

1-25 of 38 results

1 2

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Partnerships & funding